Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma

Leukemia

Volumn 17, Issue 12, 2003, Pages 2513-2516

  Fischer, M ^a   Bijman, M ^a,c   Molin, D ^a   Cormont, F ^b   Uyttenhove, C ^b   van Snick, J ^b   Sundstrom C ^a   Enblad, G ^a   Nilsson, G ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Ludwig Institute of Cancer Research   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hodgkin's lymphoma; IL 13; IL 9; Negative prognostic factors; Serum levels

Indexed keywords

CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 9;

ADVANCED CANCER; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER CLASSIFICATION; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOGLOBIN DETERMINATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SEROLOGY; SYMPTOMATOLOGY;

EID: 0346025549     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403123     Document Type: Article

References (29)

1. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13 (Suppl 1): 52-56.
2. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283-4297.
3. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997; 18: 156-163.
4. Pinto A, Gattei V, Zagonel V, Aldinucci D, Degan M, De Iuliis A et al. Hodgkin's disease: a disorder of dysregulated cellular cross-talk. Biotherapy 1998; 10: 309-320.
5. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991; 78: 1311-1317.
6. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988; 85: 6934-6938.
7. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rude E et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990; 20: 1413-1416.
8. Demoulin JB, Renauld JC. Interleukin 9 and its receptor: an overview of structure and function. Int Rev immunol 1998; 16: 345-364.
9. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 2003; 170: 3461-3467.
10. Gruss HJ, Brach MA, Drexler HG, Bross KJ, Herrmann F. Interleukin 9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992; 52: 1026-1031.
11. Renauld JC, Kermouni A, Vink A, Louahed J, Van Snick J. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukoc Biol 1995; 57: 353-360.
12. Pilette C, Ouadrhiri Y, Van Snick J, Renauld JC, Staquet P, Vaerman JP et al. IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytes through TGF-beta. J Immunol 2002; 168: 4103-4111.
13. Louahed J, Zhou Y, Maloy WL, Rani PU, Weiss C, Tomer Y et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood 2001; 97: 1035-1042.
14. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939-1946.
15. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001; 97: 250-255.
16. Fiumara P, Cabanillas F, Younes A. Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood 2001; 98: 2877-2878.
17. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
18. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001; 114: 616-623.
19. Jenmalm MC, Van Snick J, Cormont F, Salman B. Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children. Clin Exp Allergy 2001; 31: 1528-1535.
20. Kadin ME, Agnarsson BA, Ellingsworth LR, Newcom SR. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol 1990; 136: 1209-1214.
21. Ohshima K, Sugihara M, Suzumiya J, Haraoka S, Kanda M, Shimazaki K et al. Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Pathol Res Pract 1999; 195: 149-155.
22. Newcom SR, Tagra KK. High molecular weight transforming growth factor beta is excreted in the urine in active nodular sclerosing Hodgkin's disease. Cancer Res 1992; 52: 6768-6773.
23. Hsu SM, Hsu PL. Autocrine and paracrine functions of cytokines in malignant lymphomas. Biomed Pharmacother 1994; 48: 433-444.
24. Skinnider BF, Kapp U, Mak TW. Interleukin 13: a growth factor in Hodgkin lymphoma. Int Arch Allergy Immunol 2001; 126: 267-276.
25. Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grencis R et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 1998; 160: 3989-3996.
26. Gounni AS, Gregory B, Nutku E, Aris F, Latifa K, Minshall E et al. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 2000; 96: 2163-2171.
27. Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993; 11: 187-193.
28. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000; 95: 1207-1213.
29. Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002; 119: 122-124.